Table 1. Clinico-pathological Correlation of NTKL Expression in 138 HCCs.
| Clinicopathological features | Number (n) | NTKL gene expression | P* | |
|---|---|---|---|---|
| Without overexpression | With overexpression | |||
| Gender | ||||
| Male | 116 | 96(82.7%) | 20(17.3%) | |
| Female | 22 | 18(81.8%) | 4(18.2%) | 1 |
| Age | ||||
| < 60 | 111 | 93(83.8%) | 18(16.2%) | |
| ≥ 60 | 27 | 21(77.8%) | 6(22.2%) | 0.571 |
| HbsAg† | ||||
| Negative | 30 | 26(86.7%) | 4(13.3%) | |
| Positive | 90 | 72(80.0%) | 18(20.0%) | 0.674 |
| Serum AFP (ng/ml) | ||||
| < 500 | 69 | 57(82.6%) | 12(17.4%) | |
| ≥ 500 | 50 | 40(80.0%) | 10(20.0%) | 0.812 |
| Tumor size(cm) ‡, § | ||||
| ≤ 5 | 36 | 32(88.9%) | 4(11.1%) | |
| > 5 | 85 | 67(78.8%) | 18(21.2%) | 0.302 |
| Cirrhosis§ | ||||
| Absent | 36 | 21(58.3%) | 15(41.7%) | |
| Present | 81 | 41(50.6%) | 40(49.4%) | 0.440 |
| Tumor encapsulation§ | ||||
| Absent | 47 | 39(83.0%) | 8(17.0%) | |
| Present | 70 | 56(80.0%) | 14(20.0%) | 0.187 |
| Vascular Invasion | ||||
| Negtive | 71 | 59(83.1%) | 12(16.9%) | |
| Micro | 6 | 2(33.3%) | 4(66.7%) | |
| Major | 8 | 7(87.5%) | 1(12.5%) | 0.012 |
| Tumor stage(TNM)§ | ||||
| Stage I | 54 | 46(85.2%) | 8(14.8%) | |
| Stage II | 30 | 24(80.0%) | 6(20.0%) | |
| Stage III | 34 | 27(79.4%) | 7(20.6%) | 0.738 |
*
Two–sided χ2 test;
†
Hepatitis B surface antigen;
‡
Tumor size was measured by the length of the largest tumor nodule;
§
Partial data is not available, and statistic was based on available data.